Edward M. Sellers - Publications, H-index & Citations

Edward M. Sellers

university of toronto

85H指数

519论文数

3.8W被引数

收录论文 85

发表时间

Tutorial Drug-Drug Interactions

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2025-12-23

OAAI

Sellers, Edward M.

Identification of Optimal Measures of Human Abuse Potential A Post Hoc Assessment of 19 Studies

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

IF2.8

2020-10-21

PREAI

Shram, Megan J.; Levy-Cooperman, Naama; Ratcliffe, Sian; Mills, Catherine; Bartlett, Cynthia; Chen, Nancy; Setnik, Beatrice; Sellers, Edward M.; Schoedel, Kerri A.

Opioids: The Painful Public Health Reality

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2018-05-16

OAAI

Tyndale, Rachel F.; Sellers, Edward M.

Psychedelic Drugs as Therapeutics: No Illusions About the Challenges

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2017-08-24

PREAI

Sellers, Edward M.; Leiderman, Deborah B.

Psilocybin: Good Trip or Bad Trip

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2017-05-26

PREAI

Sellers, E. M.

Evaluation of human abuse liability of JZP-110

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2017-02-01

PREAI

Carter, Lawrence P.; Sellers, Edward; Henningfield, Jack; Wang, Grace; Lu, Yuan; Kelsh, Debra; Vince, Bradley

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2016-12-01

OAAI

Levy-Cooperman, N.; McIntyre, G.; Bonifacio, L.; McDonnell, M.; Davenport, J. M.; Covington, P. S.; Dove, L. S.; Sellers, E. M.

Deconstructing Designer Drugs

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2016-11-16

PREAI

Sellers, E. M.

The Effect of an Abuse-Deterrent Opioid Formulation (OxyContin) on Opioid Abuse-Related Outcomes in the Postmarketing Setting

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2016-06-22

OAAI

Coplan, P. M.; Chilcoat, H. D.; Butler, S. F.; Sellers, E. M.; Kadakia, A.; Harikrishnan, V.; Haddox, J. D.; Dart, R. C.

Claudio A. Naranjo, MD (1945-2014) OBITUARY

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2014-11-25

PREAI

Sellers, Edward M.

Abuse deterrent opiate formulations: an imperfect solution to a perfect storm?

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2014-10-01

PREAI

Sellers, E.; Romach-Sellers, M.

Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users

CNS DRUGS

IF7.4

2014-03-14

PREAI

Cruz, Hans G.; Hoever, Petra; Chakraborty, Bijan; Schoedel, Kerri; Sellers, Edward M.; Dingemanse, Jasper

From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists

TRENDS IN PHARMACOLOGICAL SCIENCES

IF19.9

2013-10-01

PREAI

Higgins, Guy A.; Sellers, Edward M.; Fletcher, Paul J.

Explicit claims for tamper resistant and abuse deterrent opiates: FDA draft guidance

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2013-10-01

PREAI

Sellers, E. M.; Romach, M. K.

Update on tamper-resistant drug formulations

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2013-06-01

PREAI

Romach, M. K.; Schoedel, K. A.; Sellers, E. M.

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations

PAIN

IF5.5

2012-12-01

OAAI

Comer, Sandra D.; Zacny, James P.; Dworkin, Robert H.; Turk, Dennis C.; Bigelow, George E.; Foltin, Richard W.; Jasinski, Donald R.; Sellers, Edward M.; Adams, Edgar H.; Balster, Robert; Burke, Laurie B.; Cerny, Igor; Colucci, Robert D.; Cone, Edward; Cowan, Penney; Farrar, John T.; Haddox, J. David; Haythornthwaite, Jennifer A.; Hertz, Sharon; Jay, Gary W.; Johanson, Chris-Ellyn; Junor, Roderick; Katz, Nathaniel P.; Klein, Michael; Kopecky, Ernest A.; Leiderman, Deborah B.; McDermott, Michael P.; O'Brien, Charles; O'Connor, Alec B.; Palmer, Pamela P.; Raja, Srinivasa N.; Rappaport, Bob A.; Rauschkolb, Christine; Rowbotham, Michael C.; Sampaio, Cristina; Setnik, Beatrice; Sokolowska, Marta; Stauffer, Joseph W.; Walsh, Sharon L.

Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence Criteria

CLINICAL THERAPEUTICS

IF3.6

2012-05-01

PREAI

Shram, Megan J.; Quinn, Anne Marie; Chen, Nancy; Faulknor, Janice; Luong, Doanh; Sellers, Edward M.; Endrenyi, Laszlo

Evaluation of the Abuse Potential of Lorcaserin, a Serotonin 2C (5-HT2C) Receptor Agonist, in Recreational Polydrug Users

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2011-03-16

PREAI

Shram, M. J.; Schoedel, K. A.; Bartlett, C.; Shazer, R. L.; Anderson, C. M.; Sellers, E. M.